Veru Inc. Logo
  • About
    • About Veru
    • Our Scientific Efforts
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Publications & Meeting Presentations
  • Pipeline
    • Cardiometabolic Obesity Drug Program
    • Cardiometabolic Inflammation Atherosclerosis Program
  • Investors
    • Investors
    • Investor Kit
    • Press Releases
    • Stock Information
    • Financial Information
      • SEC Filings
      • Annual Reports
      • IRS Form 8937
    • Investor Presentations
    • Corporate Governance
      • Letter to Shareholders
      • Board Committees
      • Governance Documents
      • Policy for Director Attendance and for Shareholder Communications with Directors
  • News
    • Veru Press Releases
    • Veru in the News
  • Contact

Press Releases

Investors

Investors

  • Investor Kit
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • IRS Form 8937
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Ratios
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports & Proxy Statements
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board Committees
    • Governance Documents
    • Letter to Shareholders
    • Policy for Director Attendance and for Shareholder Communications with Directors
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Apr 25, 2024 8:30am EDT

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Apr 01, 2024 4:05pm EDT

Veru Announces Date of 2024 Annual Meeting of Shareholders

Mar 22, 2024 4:05pm EDT

Veru Reschedules Annual Meeting of Shareholders

Mar 12, 2024 8:00am EDT

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Feb 27, 2024 7:15pm EST

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 20, 2024 8:30am EST

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 08, 2024 6:30am EST

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Feb 06, 2024 8:30am EST

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Jan 31, 2024 8:30am EST

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024 8:30am EST

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

MIAMI

Sign Up for Investor Alerts
© 2025 Veru Inc. | All Rights Reserved | Privacy Notice | Anti-Trafficking Policy | Terms of Use | Contact Us
November 2022   US-CORP-2200001 | US-CORP-2200004

You are now leaving verupharma.com.

Back to VeruPharma.com
Continue

After submission, please check your email for our opt-in notice to complete your sign-up.

Go to Top